Relevant bibliographies by topics / Cancer de la vessie

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Cancer de la vessie'

Author: Grafiati
Published: 4 June 2021
Last updated: 8 June 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cancer de la vessie.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cancer de la vessie"

1

Ruffion, A., E. Comperat, M. Roupret, and E. Chartier-Kastler. "Chapitre C - Cancer de vessie et vessie neurologique." Progrès en Urologie 17, no. 3 (May 2007): 431–35. http://dx.doi.org/10.1016/s1166-7087(07)92342-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Pointreau, Y., S. Klotz, F. Denis, and C. Durdux. "Cancer de la Vessie." Cancer/Radiothérapie 14 (November 2010): S189—S197. http://dx.doi.org/10.1016/s1278-3218(10)70023-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Irani, J., and A. Descazeaud. "Cancer de vessie : actualités 2008." Progrès en Urologie 18 (September 2008): S125—S129. http://dx.doi.org/10.1016/s1166-7087(08)73937-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Guy, L., H. Mahammedi, C. Bastide, F. Bruyere, G. Karsenty, and J. O. Bay. "Les médicaments du cancer de vessie." Progrès en Urologie 23, no. 15 (November 2013): 1238–45. http://dx.doi.org/10.1016/j.purol.2013.09.015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Xylinas, Evanguelos. "Cancer de vessie, OGE et transplantation." Progrès en Urologie - FMC 20, no. 3 (September 2010): F108—F110. http://dx.doi.org/10.1016/j.fpurol.2010.07.001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lebret, T. "Remplacement vésical et cancer de la vessie." Progrès en Urologie 19, no. 12 (December 2009): 872–80. http://dx.doi.org/10.1016/j.purol.2009.09.013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Wallerand, H. "Instillations endovésicales et cancer de la vessie." Progrès en Urologie 19, no. 12 (December 2009): 868–71. http://dx.doi.org/10.1016/j.purol.2009.09.016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

El kaddouri, H., A. Doerfler, N. Broeders, J. Nortier, A. Lemoine, T. Quackels, and T. Roumeguère. "Cancer de la vessie et transplantation rénale." Progrès en Urologie 29, no. 13 (November 2019): 671. http://dx.doi.org/10.1016/j.purol.2019.08.093.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Girard, A., J. F. Grellier, and P. Y. Salaün. "Cancers de la vessie." Médecine Nucléaire 43, no. 1 (January 2019): 69–76. http://dx.doi.org/10.1016/j.mednuc.2018.12.010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Massard, C., B. Albouy, M. Gross-Goupil, and A. Ravaud. "Nouvelles molécules dans le cancer de la vessie." Bulletin du Cancer 97, no. 3 (June 2010): S43—S50. http://dx.doi.org/10.1684/bdc.2010.1100.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Cancer de la vessie"

1

Lopez, Christophe. "Les tumeurs de vessie grade III stade PT1 : à propos de 105 cas." Montpellier 1, 1993. http://www.theses.fr/1993MON11031.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bakkar, Ashraf. "Les mutations de FGFR3 et de TP53 dans le carcinome urothélial : intérêt diagnostique et valeur pronostique." Paris 13, 2005. http://www.theses.fr/2005PA132014.

Full text
Abstract:
Dans notre hypothèse, les mutations de FGFR3 et de TP53 définissent deux voies distinctes de la pathogenèse des UCC au moment du diagnostic initial. Afin de vérifier cette hypothèse, nous avons utilisé une méthode de chromatographie liquide haute performance dénaturante (DHPLC) et séquençage, pour détecter ces mutations dans les UCCs. Nous avons recherché les relations entre le tabagisme et ces mutations. Les résultats montrent que les mutations de FGFR3 sont associées avec les tumeurs de bas stade et de bas grade, tandis que les mutations de TP53 sont associées avec des tumeurs de haut stade et de haut grade. Les mutations de ces deux gènes sont presque mutuellement exclusives. Nos résultats suggèrent que le tabagisme influence les mutations de TP53. Par opposition, les mutations de FGFR3 ne sont pas affectées par le tabac et résultent probablement d'une altération endogène. Nous avons recherché la valeur pronostique des mutations de FGFR3 et de TP53 chez des patients présentant une tumeur primitive T1G3. Les résultats montrent que les mutations de FGFR3 sont associées avec un taux faible de progression (p<0. 04), et une meilleure survie spécifique. Les patients, présentant le génotype FGFR3 muté/ TP53 normal, ont une meilleure survie comparée aux patients ayant le génotype FGFR3 normal/ TP53 muté. Nous avons développé un test (AS-PCR) pouvant détecter les mutations de FGFR3, dans les tumeurs et dans les urines des patients. La méthode AS-PCR est simple, spécifique et sensible pour la détection des mutations de FGFR3.
APA, Harvard, Vancouver, ISO, and other styles
3

Berrahmoune, Saoussen Bezdetnaya-Bolotine Lina. "Étude des mécanismes régissant l'efficacité photodynamique sélective de l'Héxylaminolévulinate-Protoporphyrine IX dans le traitement du cancer de la vessie Application dans le cadre de la prévention de ses récidives /." S. l. : Nancy 1, 2009. http://www.scd.uhp-nancy.fr/docnum/SCD_T_2009_0012_BERRAHMOUNE.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Berrahmoune, Saoussen. "Étude des mécanismes régissant l’efficacité photodynamique sélective de l’Héxylaminolévulinate-Protoporphyrine IX dans le traitement du cancer de la vessie : Application dans le cadre de la prévention de ses récidives." Thesis, Nancy 1, 2009. http://www.theses.fr/2009NAN10012/document.

Full text
Abstract:
La thérapie photodynamique (PDT) est basée sur l’action d’un photosensibilisateur qui en présence de la lumière et de l’oxygène induit la synthèse d’espèces réactives de l’oxygène, toxiques pour les cellules. La PDT a été utilisée pour le traitement et la prévention du cancer de la vessie. Les études ont été réalisées in vivo. La PDT a été développé en utilisant l’Hexvix® précurseur de la protoporphyrine IX (PpIX). Les paramètres biologiques liés à la PpIX et qui régissent l’efficacité du traitement photodynamique des tumeurs vésicales ont été déterminés en fonction de deux concentrations d’Hexvix® (8 et 16 mM) induisant des effets photodynamiques diamétralement opposés. L’efficacité du traitement photodynamique obtenue pour 8 mM d’Hexvix® est liée à la localisation mitochondriale de la PpIX induisant des dommages pro-apoptotiques. La PDT entraîne la diminution significative du pourcentage de l’implantation tumorale après la TUR et permet ainsi de prévenir les récidives du cancer de la vessie
Photodynamic therapy (PDT) is a treatment modality based on the cytotoxic effect occurring on target tissues by interaction of a photosensitizer with light in the presence of oxygen. The aim of this study was to optimise PDT for treatment and prevention of recurrence of bladder cancer. The study was performed in vivo. PDT was performed with Hexvix® a precursor of the photosentitizer protoporphyrin IX (PpIX). First, we executed a mechanistic analysis of differential PDT effects according to Hexvix® concentration. 8 or 16 mM induced diametrically opposed photodynamic effects. PDT efficacy is depends on the mitochondrial localization of PpIX and its concentration and leads to pro-apoptotic damages. Second, PDT was performed in a rat model mimicking post fluorescence guided TUR. The amount of viable tumor cell within the bladder lumen significantly decreased with PDT and resulted in a significant reduction of tumor implantation
APA, Harvard, Vancouver, ISO, and other styles
5

Braud, Guillaume Bouchot Olivier. "Cystectomie totale pour cancer de vessie mortalité, morbidité et résultats carcinologiques /." [S.l.] : [s.n.], 2005. http://theses.univ-nantes.fr/thesemed/SPEbraud.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Le, Bacquer Anne-Véronique. "Les complications de la BCG-thérapie endovésicale dans le traitement des cancers superficiels de "la vessie" : revue générale à propos d'un cas." Montpellier 1, 1995. http://www.theses.fr/1995MON11047.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Delbos, Olivier. "Entérocystoplastie sigmoi͏̈dienne détubulée : nouveau procédé d'anastomose vésico-urétrale et résultats fonctionnels : à propos de 10 observations." Montpellier 1, 1995. http://www.theses.fr/1995MON11068.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Godesence, Carole. "Place de la radiotherapie dans les cancers infiltrants de la vessie : revue generale." Lille 2, 1990. http://www.theses.fr/1990LIL2M304.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

PIETRI, MOROSOFF BRIGITTE. "Contribution a l'etude de la curietherapie dans les cancers de la vessie." Aix-Marseille 2, 1988. http://www.theses.fr/1988AIX20377.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Besancon, Marjorie. "Immunothérapie non-spécifique du cancer de la vessie : développement de nouvelles approches basées sur la combinaison d'agents thérapeutiques." Doctoral thesis, Université Laval, 2017. http://hdl.handle.net/20.500.11794/27996.

Full text
Abstract:
Le cancer de la vessie est au niveau mondial le 9ème cancer en importance avec 430 000 nouveaux cas diagnostiqués en 2014. Les tumeurs vésicales infiltrant le muscle représentent environ 25% des tumeurs au premier diagnostic, alors que les tumeurs vésicales non infiltrant le muscle représentent environ 75% de ces tumeurs. Ces dernières sont généralement associées à un bon pronostic mais sont caractérisées par un taux élevé de récidive et de progression, alors que les premières sont d’emblée agressives et présentent un risque élevé de progression vers les stades avancés de la maladie. Parmi les différentes thérapies disponibles pour la prise en charge des tumeurs vésicales on retrouve l’immunothérapie non-spécifique par le Bacillus de Calmette-Guérin (BCG) pour les tumeurs non-infiltrant le muscle et, depuis peu, les inhibiteurs de point de contrôle immunologique (PCI) pour les tumeurs à des stades avancés. Le cancer de la vessie est un des rares cancers à bien répondre à l’immunothérapie, mais malgré cela ces traitements ne sont pas optimaux. L’objectif principal de mon projet était de développer de nouvelles approches immunothérapeutiques plus efficaces pour lutter contre les cancers de la vessie. Pour ce faire, trois approches complémentaires ont été investiguées dans des modèles murins de cancer de la vessie. Dans un premier temps, nous avons évalué in vitro et in vivo le potentiel du poly(I:C), un agoniste du TLR3, utilisé seul ou en combinaison avec le BCG. Alors que le poly(I:C) a induit une diminution de la prolifération et une induction de l’apoptose dans des cellules de cancer de la vessie traitées in vitro, la combinaison poly(I:C)/BCG a induit, in vivo, une régression tumorale complète chez 28% des souris traitées. Par la suite, nous avons évalué le potentiel de deux combinaisons d’inhibiteurs de PCI dans deux modèles murins différents de cancer de la vessie. La première combinaison étudiée est celle du blocage simultané des PCI PD-1 et TIM-3 testée dans le modèle MBT-2 puisque que la caractérisation des tumeurs MBT-2 a montré que ces deux récepteurs étaient des PCI fréquemment exprimés dans ces tumeurs. Le blocage in vivo de ces voies de signalisation a révélé que, dans les tumeurs MBT-2, PD-1 est associé à une activité pro-tumorale, alors que de façon étonnante, TIM-3 est associé à une activité anti-tumorale, révélant des fonctions opposées de ces deux PCI dans ces tumeurs. La seconde combinaison étudiée est celle des PCI PD-1 et LAG-3 testée cette fois-ci dans le modèle MB49. La caractérisation des tumeurs MB49 a démontré que PD-1 et LAG-3 étaient des PCI importants dans ces tumeurs. L’étude in vivo a démontré que l’inhibition conjointe des voies PD-1 et LAG-3 doublait le taux de survie, puisque 67% des souris démontraient une régression tumorale complète alors que les taux de survie étaient respectivement de 33% et 0% lorsque les anti-PD-1 et anti-LAG-3 étaient administrés en monothérapie. Finalement, puisque les androgènes semblent jouer un rôle important dans le cancer de la vessie, nous avons testé une approche combinant l’inhibition de PD-1 et du récepteur aux androgènes (AR). Nous avons démontré que l’enzalutamide et le seviteronel, des anti-androgènes de deuxième génération, induisaient in vitro une diminution de la prolifération des cellules de cancer de la vessie humaines et murines. In vivo, la combinaison d’enzalutamide et d’anti-PD-1 a démontré un taux de survie de 66%, soit un taux bien supérieur au taux de 16% observé lors de l’utilisation de l’enzalutamide ou de l’anti-PD-1 utilisés en monothérapie. Ces études ont ainsi permis d’identifier différentes avenues possibles, pour augmenter la réponse immune anti-tumorale, qui pourraient être testées en essais cliniques. Elles démontrent également que la combinaison d’approches thérapeutiques est très prometteuse pour l’avenir de l’immunothérapie du cancer de la vessie.
Bladder cancer (BCa) is the ninth most common cancer in the world, with 430 000 new cases diagnosed in 2014. Muscle-invasive bladder cancer represents about 25% of bladder tumors, while non-muscle-invasive bladder cancer represents about 75% of these tumors. The latter are usually associated with a favorable prognosis but are characterized by a high rate of recurrence and progression while the former are aggressive from the onset and are at high risk of progression toward advanced disease. Among the various therapies available for the management of bladder tumors is non-specific immunotherapy using bacillus Calmette-Guerin (BCG) for the treatment on non-muscle invasive bladder tumors and, more recently, inhibitors of immune checkpoint (IC) for the treatment of advanced bladder tumors. BCa is one of the rare cancers to respond well to immunotherapy but, nevertheless, these treatments are suboptimal. The main objective of my project was to develop new immunotherapeutic approaches to fight more efficiently against BCa. To achieve this, three complementary approaches were investigated in murine BCa models. We first assessed in vitro and in vivo the potential of poly(I:C), a TLR3 agonist, used alone or in combination with BCG. While poly(I:C) induced anti-proliferative and apoptotic effects on BCa cells in vitro, the combination of poly(I:C) and BCG induced in vivo a complete tumor regression in 28% of treated mice. Then, we evaluated the potential of two combinations of IC inhibitors in two murine BCa models. The first combination studied was that of the simultaneous blockade of PD-1 and TIM-3 tested in the MBT-2 model because the characterization of the MBT-2 tumors showed that these two receptors where frequently IC expressed in these tumors. In vivo blockade of these pathways revealed that in MBT-2 tumors, PD-1 is associated to a pro-tumoral activity, whereas, TIM-3 is associated with anti-tumoral activity, revealing opposite functions of these IC in these tumors. The second combination studied was that of PD-1 and LAG-3 tested in the MB49 BCa model. The characterization of MB49 tumors showed that PD-1 and LAG-3 were important IC in these tumors. The in vivo study showed that the simultaneous blockade of PD-1 and LAG-3 increased the survival rate, since 67% of mice showed a complete tumor regression while the survival rates were 33% and 0% when anti-PD-1 and anti-LAG-3, respectively, were used in monotherapy. Finally, since androgens seem to play an important role in BCa, we tested an approach combining the inhibition of PD-1 and of the androgen receptor (AR). We showed that enzalutamide and seviteronel, two second generation antiandrogens, induced in vitro a decrease of the proliferation of human and murine BCa cells. In vivo, the combination of enzalutamide with anti-PD-1 showed a 66% overall survival rate, a rate that is much higher than the 16% rate observed when enzalutamide or anti-PD-1 were used alone. Thus, these studies allowed us to identify various possible ways to increase anti-tumor immune response that could be tested in clinical trials. They also show that the combination of therapeutic approaches is very promising the future of BCa immunotherapy.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Cancer de la vessie"

1

L, Denis, ed. Developments in bladder cancer: Proceedings of the First International Consensus Development Conference on Guidelines for Clinical Research in Bladder Cancer, held in Antwerp, Belgium, June 20-22, 1985. New York: A.R. Liss, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Debruyne, F. M. J., 1941-, Denis L, Meijden, Ad P. M. van der., European Organization for Research on Treatment of Cancer. Genito-Urinary Tract Cancer Cooperative Group., and International Workshop on BCG in Superficial Bladder Cancer (1st : 1988 : Kerkrade, Netherlands), eds. BCG in superficial bladder cancer: Proceedings of an EORTC Genitourinary Group sponsored meeting held at Erenstein Castle Kerkrade, the Netherlands, on September 7-8, 1988, organized by the Department of Urology, University of Nijmegen, the Netherlands. New York: A.R. Liss, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

International SELECTRON Users' Meeting (5th 1988 The Hague). Brachytherapy 2: Proceedings of the 5th International SELECTRON Users' Meeting 1988 The Hague-The Netherlands. Edited by Mould R. F. 1939-. Leersum: Nucletron, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Timmermann, Carsten, and Elizabeth Toon, eds. Cancer Patients, Cancer Pathways. London: Palgrave Macmillan UK, 2012. http://dx.doi.org/10.1057/9781137272089.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Wyatt, Debbie, and Nicholas Hulbert-Williams. Cancer and Cancer Care. 1 Oliver’s Yard, 55 City Road London EC1Y 1SP: SAGE Publications Ltd, 2015. http://dx.doi.org/10.4135/9781473920620.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Frohmüller, H. G. W. 1928- and Wirth Manfred P, eds. Uro-oncology: Current status and future trends : proceedings of a Uro-Oncological Workshop, held in Würzburg, Federal Republic of Germany, June 22-25, 1988. New York: Wiley-Liss, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

National Cancer Institute (U.S.), ed. President's Cancer Panel, National Cancer Program: Cancer and poverty. Silver Spring, Md: Eberlin Reporting Center, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Biology of cancer: Cancer genetics. New York NY: Chelsea House, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

L, Slevin Maurice, and Scott Ronald Bodley Sir, eds. Cancer. 2nd ed. Oxford: Oxford University Press, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bose, S. M. Cancer. New Delhi: National Book Trust, India, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Cancer de la vessie"

1

Grosclaude, P., M. Sauvage, and M. Velten. "Vessie." In Survie des patients atteints de cancer en France, 299–307. Paris: Springer Paris, 2007. http://dx.doi.org/10.1007/978-2-287-39310-5_39.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Boyle, H., A. Fléchon, and J. P. Droz. "Cancer de la vessie/uretère." In Thérapeutique du cancer, 485–94. Paris: Springer Paris, 2011. http://dx.doi.org/10.1007/978-2-8178-0021-9_30.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Matsuda, Minoru, Tadatoshi Takayama, Young-Woo Kim, and Seong Yeop Ryu. "Ultrasonically Activated Device and Vessel-Sealing Device." In Laparoscopic Gastrectomy for Cancer, 49–52. Tokyo: Springer Japan, 2012. http://dx.doi.org/10.1007/978-4-431-54003-8_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bard, Robert L. "Doppler Histogram Vessel Density Analysis." In Image Guided Prostate Cancer Treatments, 71–82. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-40429-0_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Matau, A., and C. Roy. "Tumeurs de la vessie et de l’urètre." In IRM du pelvis de l’homme et de la femme, 93–111. Paris: Springer Paris, 2014. http://dx.doi.org/10.1007/978-2-8178-0428-6_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Zhang, Hongbin, Kun Zhang, Li Chen, Jianguo Wu, Peijian Zhang, and Huiyu Zhou. "Automatic Measurement of Blood Vessel Angles in Immunohistochemical Images of Liver Cancer." In Communications in Computer and Information Science, 162–72. Singapore: Springer Singapore, 2017. http://dx.doi.org/10.1007/978-981-10-6370-1_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Bullitt, Elizabeth, Nancy U. Lin, Matthew G. Ewend, Donglin Zeng, Eric P. Winer, Lisa A. Carey, and J. Keith Smith. "Tumor Therapeutic Response and Vessel Tortuosity: Preliminary Report in Metastatic Breast Cancer." In Medical Image Computing and Computer-Assisted Intervention – MICCAI 2006, 561–68. Berlin, Heidelberg: Springer Berlin Heidelberg, 2006. http://dx.doi.org/10.1007/11866763_69.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Maione, Federica, and Enrico Giraudo. "Tumor Angiogenesis: Methods to Analyze Tumor Vasculature and Vessel Normalization in Mouse Models of Cancer." In Methods in Molecular Biology, 349–65. New York, NY: Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4939-2297-0_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Férrière, J. M., P. Brucher, and M. Le Guillon. "Etude Functionelle et Urodynamique de la Vessie Ileo-caecale Detublisée." In 40. Tagung, 28. September–1. Oktober 1988, Saarbrücken, 169. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-83800-2_115.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Santos-Costa, Paulo, Filipe Paiva-Santos, Rafael A. Bernardes, Liliana B. Sousa, Filipa Ventura, João Faria, Isabel Gil, et al. "Difficult Intravenous Access in Older Adults with Cancer: Can Vein-Locating Technology Be Key for Vessel Health?" In Gerontechnology V, 241–50. Cham: Springer Nature Switzerland, 2023. http://dx.doi.org/10.1007/978-3-031-29067-1_24.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Cancer de la vessie"

1

Buzatto, Isabela Panzeri Carlotti, Daniel Guimarães Tiezzi, Sarah Abud Recife, Ruth Morais Bonini, Licerio Miguel, Liliane Silvestre, Nilton Onari, and Ana Luiza Peloso Araujo Faim. "Machine learning can reliably predict malignancy of BI-RADS 4a and 4b breast lesions based on clinical and ultrasonographic features." In Brazilian Breast Cancer Symposium 2023. Mastology, 2023. http://dx.doi.org/10.29289/259453942023v33s1002.

Full text
Abstract:
Objective: The objectives of this study were to establish the most reliable machine learning model to predict malignancy in BI-RADS 4a and 4b breast lesions and optimize the negative predictive value to minimize unnecessary biopsies. Methodology: We included clinical and ultrasonographic attributes from 1,250 breast lesions from four institutions classified as BI-RADS 3, 4a, 4b, 4c, 5, and 6. We selected the most informative attributes to train the models in order to make inferences about the diagnosis of BI-RADS 4a and 4b lesions (validation dataset). Using the best parameters and hyperparameters selected, we tested the performance of nine models and 1,530 ensemble models. Results: The most informative attributes were shape, margin, orientation, and size of the lesions, the resistance index of the internal vessel, the age of the patient, and the presence of a palpable lump. The highest mean NPV was achieved with XGBoost (93.6%). The final performance of the best ensemble model was NPV=96.4%, sensitivity=81.5%, specificity=84.1%, PPV=46.8%, f1-score=59.5%, and the final accuracy=83.7%. Age was the most important attribute to predict malignancy. The use of the final model associated with the patient’s age would reduce by 51% the number of biopsies in women with BI-RADS 4a or 4b lesions. Conclusion: Machine learning can predict malignancy in BI-RADS 4a and 4b breast lesions identified by ultrasonography, based on clinical and ultrasonographic features. Our final prediction model would be able to avoid 51% of the 4a and 4b breast biopsies, without missing any cancers.
APA, Harvard, Vancouver, ISO, and other styles
2

Whipple-Bettes, RA, EM Balzer, JR Yoon, EH Cho, MA Matrone, and SS Martin. "Targeting novel microtentacles to reduce the adhesion of circulating tumor cells to blood vessel walls." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-2044.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Mazzone, Massimiliano. "Abstract IA06: Influence of macrophage metabolism on vessel shape: Implications for cancer." In Abstracts: AACR Special Conference: The Function of Tumor Microenvironment in Cancer Progression; January 7-10, 2016; San Diego, CA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.tme16-ia06.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Goulart, Ana Filipa Ferreira, Régis Resende Paulinelli, Horácio Mendonza, and Luiz Fernando Jubé Ribeiro. "Bilobed LICAP for breast conservation: Technique description and 10-year retrospective cohort results." In Brazilian Breast Cancer Symposium 2023. Mastology, 2023. http://dx.doi.org/10.29289/259453942023v33s1035.

Full text
Abstract:
Objective: The bilobed flap is a useful double transposition flap technique for covering skin defects, particularly in the face. Lateral intercostal perforator vessel flaps (LICAPs) are a valuable volume replacement oncoplastic technique for the outer quadrants. A plastic surgeon in Brazil has modified the bilobed flap for use in the breast, especially for tumors located in the upper inner quadrants. The aim of this study is to describe a new modification, called bilobed LICAP, for tumors located in the central quadrants or nearby, and our results after 10 years. Methodology: From 2013 to 2023, we identified 37 patients submitted to this technique, with large malignant breast tumors near or involving the skin in the central quadrants or nearby, who did not have ptosis or did not wish to correct it, and for whom this new modified bilobed flap technique avoided mastectomy. These patients were operated on by the same breast oncoplastic surgeon in different institutions, and this is part of a research project approved by our ethical committee (n. 2.322.212). Results: The mean age of patients was 56.23 (±13.57) years, and the estimated breast volume was 350 (±124.74) g. A total of 24 (88.89%) women had grade 0 or 1 ptosis. The mean specimen weight was 105.89 (±127.00) g, and the mean clinical tumor size was 45.00 (±16.49) mm, with tumors up to 75 mm. There were 13 (35.14%) tumors larger than 5 cm and one multicentric tumor. Notably, 34 (91.89%) patients had invasive ductal carcinomas. Round incisions over the tumor were performed in 36 (97.30%) cases, and the skin was preserved, and part of the flap de-epithelialized in one case. Nipple areola complex was removed due to clinical involvement in 19 (51.35%) cases. In two of these cases, the nipple and areola were immediately reconstructed with contralateral free grafting. A total of 20 (54.05%) patients required neoadjuvant chemotherapy, and 10 (27.03%) received adjuvant chemotherapy. Four patients received anti-HER therapy (13.04%) and 20 (86.96%) received hormone therapy. Three (8.11%) patients underwent immediate contralateral mastopexy due to previous asymmetry. Radiotherapy was indicated in all cases. Notably, 18 (88.24%) patients received hormone therapy. There were 3 (8.11%) minor complications, including one case of hyperemia treated with antibiotics, one small hematoma treated clinically, and one case of palpable lump and retraction due to fat necrosis in a patient with previous mammoplasty. There was one case of focally positive margin, treated with radiotherapy, without re-excision. Intraoperative pathological margin evaluation was performed in 14 (46.77%) cases. There were no cases of dehiscence, skin necrosis, seroma, enlarged scars, thromboembolism, or other complications. All patients were satisfied, and none of them required surgical revision. There were no cases of conversion to mastectomy. Notably, 19 (51.35%) patients returned after radiotherapy for aesthetic follow-up and evaluation with the oncoplastic surgeon. The rest continued their follow-up with other surgical or clinical oncologists. In a median follow-up of 20 (13–66) months, there were no cases of local recurrence, metastasis, or death. According to the BREAST-Q, patient satisfaction with their breasts was 74.41 (±17.92), satisfaction with the results was 91.06 (±11.89), psychosocial well-being was 80.19 (±17.12), sexual well-being was 75.92 (±24.63), physical well-being was 68.25 (±14.05), satisfaction with information was 84.64 (±15.83), and satisfaction with the surgeon was 97.67 (±6.95). Aesthetic results were rated as good or excellent in 17 (89.47%) cases by the Harris scale and in 14 (73.68%) by the BCCT.core software. Conclusion: The new technique allowed for breast conservation in all cases, even those requiring large central resections on proportionally small breasts with limited ptosis. The procedure resulted in high rates of free surgical margins, good or excellent symmetry in most cases, no need for surgical revisions, and few complications.
APA, Harvard, Vancouver, ISO, and other styles
5

Nagayama, Katsuya, Yuki Oshiumi, and Masayuki Yumita. "3D Particle Simulation on Cancer Growth and Angiogenesis - Using 2D Blood Vessel Image." In 2012 Spring Congress on Engineering and Technology (S-CET). IEEE, 2012. http://dx.doi.org/10.1109/scet.2012.6342029.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Munoz, Adam, Joseph Miller, and Cynthia A. Reinhart-King. "Abstract A15: Development of anin vitro3D vessel-spheroid model for investigating cancer metastasis." In Abstracts: AACR Special Conference: Engineering and Physical Sciences in Oncology; June 25-28, 2016; Boston, MA. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.epso16-a15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Voigt, Elizabeth, Cara F. Buchanan, M. Nichole Rylander, and Pavlos Vlachos. "Blood Flow Characterization in a Perfused Collagen Vessel Bioreactor Using X-Ray Micro-PIV." In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80700.

Full text
Abstract:
Newly developed cancer therapies must pass through a series of increasingly complex testing regimens before obtaining FDA approval as valid treatments. The costs of these tests increase rapidly as the physiological accuracy of the platform increases, from initial proof-of-concept in static tissue cultures, to treatment of animal models, and ultimately to human clinical trials. Three-dimensional engineered blood-perfused tumor models are becoming increasingly important as intermediate platforms for the study and treatment of cancer, as they are superior to static two-dimensional cultures in their reproduction of relevant physiological conditions and are inexpensive in comparison to animal models. Because of this, the design of well-characterized adaptable in vitro vascular tumor models has become a central objective of the emerging field of tumor engineering. Characterization of the flow within three-dimensional tumor models is critical for quantifying fluid shear stress and determining its role in pivotal tumor development processes such as tumor cell angiogenesis and metastasis. Ultimately, this knowledge will provide new avenues for therapeutic modulation of the tumor microenvironment.
APA, Harvard, Vancouver, ISO, and other styles
8

Rada, Miran, Migmar Tsamchoe, Audrey Kapelanski-Lamoureux, Jessica Bloom, Stephanie Petrillo, Sébastien Tabariès, Diane H. Kim, et al. "Abstract 1927: Cancer cells induce apoptosis in hepatocytes as one of the mechanisms to displace hepatocytes in vessel co-opted colorectal cancer liver metastases." In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-1927.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hussein, Ola, Feras Alali, Ala-Eddin Al Moustafa, and Ashraf Khalil. "Design, Synthesis and Biological Evaluation of Novel Chalcone Analogs as Potential Therapeutic Agents for Castration-Resistant Prostate Cancer." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0179.

Full text
Abstract:
Prostate cancer (PCa) is the second most frequently diagnosed malignancy, as well as a leading cause of cancer-related mortality in men globally. Despite the initial response to hormonal targeted therapy, the majority of patients ultimately progress to a lethal form of the disease, termed as castration-resistant prostate cancer (CRPC), which currently lacks curative therapeutic options and is associated with poor prognosis. Therefore, the development of novel treatment modalities for PCa is urgently needed. Chalcones, also known as 1,3-diphenyl-2-propen-1-ones, are among the highly attractive scaffolds being investigated for their antitumor activities. Three series of 18 cyclic (tetralone-based) and two acyclic chalcone analogs, in which ring B was either substituted with nitrogen mustard or replaced by pyrrole or pyridine heterocyclic rings, were designed, synthesized and evaluated as potential therapies for CRPC. Compounds were synthesized by Claisen-Schmidt condensation reaction, purified using columnchromatography or recrystallization and characterized by 1H-NMR, 13C-NMR and LC-MS. The compounds' in-vitro cytotoxicity was evaluated against three prostate cancer cell lines (PC3, DU145, and LNCaP). Among the tested compounds, OH14, OH19 and OH22 showed potent antiproliferative activities at low micromolar levels with IC50 values ranging between 4.4 and 10 µM against PC3 and DU145 cell lines. Detailed biological studies of the lead molecule OH19 revealed that it significantly induces apoptosis through upregulation of Bax and downregulation of BCL-2. In addition, OH19 potently inhibits colony formation and reduces cell migration of androgen-independent PCa cell lines (PC3 and DU145). The molecular pathway analysis show that the anticancer activity of OH19 is associated with attenuation in the phosphorylation of Akt and ERK. Furthermore, OH19 inhibits blood vessel formation in the chick chorioallantoic membrane (CAM) model as compared to control. These results indicate that OH19 could serve as a potential promising lead molecule for the treatment of CRPC and thus, further in-vitro and invivo studies are warranted.
APA, Harvard, Vancouver, ISO, and other styles
10

Wu, Shan, Yu Wang, Jinsong Guo, Qunzhi Chen, Jue Zhang, and Jing Fang. "Nanosecond pulsed electric fields inhibit breast cancer development and suppress tumor blood vessel growth." In 2013 IEEE 40th International Conference on Plasma Sciences (ICOPS). IEEE, 2013. http://dx.doi.org/10.1109/plasma.2013.6634807.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Cancer de la vessie"

1

Line, Bruce R., Antonio Passaniti, Carol Lambert, and Ron Mease. Evaluation of Radiolabeled Tumor Vessel Targeting Peptides as Novel Agents for the Staging and Therapy of Human Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, February 2002. http://dx.doi.org/10.21236/ada406974.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Cooney, Kathleen A. Prostate Cancer Aggressiveness Genes in Hereditary Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, March 2005. http://dx.doi.org/10.21236/ada446359.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Cooney, Kathleen A., and Colin Duckett. Prostate Cancer Aggressiveness Genes in Hereditary Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, March 2006. http://dx.doi.org/10.21236/ada455279.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wright, William. California Cancer Registry Enhancement for Breast Cancer Research. Fort Belvoir, VA: Defense Technical Information Center, July 1999. http://dx.doi.org/10.21236/ada374022.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Young, John L. California Cancer Registry Enhancement for Breast Cancer Research. Fort Belvoir, VA: Defense Technical Information Center, October 1995. http://dx.doi.org/10.21236/ada308093.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Wright, William. California Cancer Registry Enhancement for Breast Cancer Research. Fort Belvoir, VA: Defense Technical Information Center, October 1997. http://dx.doi.org/10.21236/ada346975.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Wright, William. California Cancer Registry Enhancement for Breast Cancer Research. Fort Belvoir, VA: Defense Technical Information Center, October 1998. http://dx.doi.org/10.21236/adb249633.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Cooney, Kathleen. Prostate Cancer Aggressiveness Gene in Hereditary Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, March 2007. http://dx.doi.org/10.21236/ada472110.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Krontiris, Theodore G., Garry P. Larson, and Yan Ding. Mapping Interactive Cancer Susceptibility Genes in Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, April 2007. http://dx.doi.org/10.21236/ada472694.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Hait, William. Genetic Susceptibility to Cancer Chemotherapy in Human Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, July 2000. http://dx.doi.org/10.21236/ada396563.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Cancer de la vessie' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography